Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement

Insight Molecular Diagnostics ( (IMDX) ) has issued an update.

On February 20, 2026, Insight Molecular Diagnostics Inc. signed a Specimen Collection Agreement with Quest Diagnostics under which Quest will provide specimen collection services for patients undergoing the company’s GraftAssureCore blood test. The deal includes fee-based payments to Quest and commits both parties to use commercially reasonable efforts, for a defined period, to negotiate additional rights related to the GraftAssure technology, potentially deepening their collaboration and expanding the test’s reach in clinical settings.

The most recent analyst rating on (IMDX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Insight Molecular Diagnostics stock, see the IMDX Stock Forecast page.

Spark’s Take on IMDX Stock

According to Spark, TipRanks’ AI Analyst, IMDX is a Neutral.

The score is held back primarily by weak financial performance—continued losses, negative operating cash flow, and balance-sheet risk—despite strong recent technical strength and a constructive earnings-call outlook driven by the upcoming FDA submission catalyst and disciplined cash management. Valuation remains constrained by lack of profitability and no dividend data.

To see Spark’s full report on IMDX stock, click here.

More about Insight Molecular Diagnostics

Insight Molecular Diagnostics Inc. operates in the molecular diagnostics and clinical testing industry, focusing on advanced blood-based assays. Its offerings include the GraftAssureCore test, a donor-derived cell-free DNA assay that uses a novel PCR-based platform to support monitoring of transplant patients and other potential registrants in specialized diagnostic markets.

Average Trading Volume: 45,482

Technical Sentiment Signal: Hold

Current Market Cap: $181.1M

For an in-depth examination of IMDX stock, go to TipRanks’ Overview page.